Order Article Reprints

Graham DY, Naser SA, Borody T, Hebzda Z, Sarles H, Levenson S, Hardi R, Arłukowicz T, Svorcan P, Fathi R, et al. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics. 2024; 13(8):694. https://doi.org/10.3390/antibiotics13080694

Graham, David Y., Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, and et al. 2024. "Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease" Antibiotics 13, no. 8: 694. https://doi.org/10.3390/antibiotics13080694

Graham, D. Y., Naser, S. A., Borody, T., Hebzda, Z., Sarles, H., Levenson, S., Hardi, R., Arłukowicz, T., Svorcan, P., Fathi, R., Bibliowicz, A., Anderson, P., McLean, P., Fehrmann, C., Harris, M. S., Zhao, S., & Kalfus, I. N. (2024). Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics, 13(8), 694. https://doi.org/10.3390/antibiotics13080694